MCID: TNG004
MIFTS: 47

Tongue Disease

Categories: Gastrointestinal diseases, Oral diseases, Smell/Taste diseases

Aliases & Classifications for Tongue Disease

MalaCards integrated aliases for Tongue Disease:

Name: Tongue Disease 12 15
Abnormality of the Tongue 30 6
Tongue Diseases 45 74
Tongue Disorders 44

Classifications:



External Ids:

Disease Ontology 12 DOID:10944
ICD9CM 36 529.9
MeSH 45 D014060
SNOMED-CT 69 69244009
ICD10 34 K14 K14.9
UMLS 74 C0040409

Summaries for Tongue Disease

MedlinePlus : 44 Your tongue helps you taste, swallow, and chew. You also use it to speak. Your tongue is made up of many muscles. The upper surface contains your taste buds. Problems with the tongue include Pain Swelling Changes in color or texture Abnormal movement or difficulty moving the tongue Taste problems These problems can have many different causes. Treatment depends on the underlying problem.

MalaCards based summary : Tongue Disease, also known as abnormality of the tongue, is related to ankyloglossia and muscular dystrophy, limb-girdle, autosomal recessive 5, and has symptoms including snoring, halitosis and oral manifestations. An important gene associated with Tongue Disease is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Endometrial cancer and Gastric cancer. The drugs Doxycycline and Cefuroxime have been mentioned in the context of this disorder. Affiliated tissues include tongue, colon and skin, and related phenotypes are homeostasis/metabolism and digestive/alimentary

Wikipedia : 77 Tongue diseases can be congenital or acquired, and are multiple in number. Considered according to a... more...

Related Diseases for Tongue Disease

Diseases related to Tongue Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 112)
# Related Disease Score Top Affiliating Genes
1 ankyloglossia 10.8
2 muscular dystrophy, limb-girdle, autosomal recessive 5 10.8
3 adult hepatocellular carcinoma 10.5 CTNNB1 TP53
4 cerebral convexity meningioma 10.5 CDH1 TP53
5 rare adenocarcinoma of the breast 10.4 AKT1 TP53
6 male reproductive system disease 10.4 AKT1 CDH1 TP53
7 extracranial arteriovenous malformation 10.4 MMP2 MMP9
8 bartholin's gland disease 10.4 CDKN2A SLC10A2 TP53
9 vulvar intraepithelial neoplasia 10.4 MMP2 TP53
10 tonsil cancer 10.4 CDH1 CDKN2A TP53
11 pre-malignant neoplasm 10.4 CDH1 CDKN2A TP53
12 focal myositis 10.4 MMP2 MMP9
13 bladder squamous cell carcinoma 10.4 CDKN2A TP53
14 in situ carcinoma 10.4 CDH1 CDKN2A TP53
15 large intestine adenocarcinoma 10.4 CDH1 CTNNB1
16 bartholin's gland benign neoplasm 10.4 CDKN2A SLC10A2
17 villous adenocarcinoma 10.4 MMP2 MMP9
18 cholecystitis 10.4 CDH1 CDKN2A TP53
19 anal squamous cell carcinoma 10.4 AKT1 CDKN2A TP53
20 keratinizing squamous cell carcinoma 10.4 CDKN2A TP53
21 bile duct adenocarcinoma 10.4 AKT1 CDH1 TP53
22 spastic entropion 10.4 MMP2 MMP9
23 infiltrating angiolipoma 10.4 CDKN2A VEGFC
24 actinic keratosis 10.4 CDKN2A MMP2 TP53
25 lentigo maligna melanoma 10.4 MMP2 MMP9
26 cell type benign neoplasm 10.4 CDKN2A CTNNB1 TP53
27 laryngeal squamous cell carcinoma 10.4 CDH1 CDKN2A TP53
28 epstein-barr virus-associated gastric carcinoma 10.4 CDH1 CDKN2A CTNNB1
29 colorectal adenocarcinoma 10.4 CDH1 CTNNB1 TP53
30 ureteral obstruction 10.4 CTNNB1 TP53 VEGFC
31 ductal carcinoma in situ 10.4 AKT1 CDH1 TP53
32 gallbladder adenoma 10.4 CDKN2A CTNNB1
33 central nervous system cancer 10.4 AKT1 CDKN2A TP53
34 nervous system cancer 10.4 AKT1 CDKN2A TP53
35 intrahepatic cholangiocarcinoma 10.4 CDH1 CTNNB1 TP53
36 serous cystadenocarcinoma 10.4 AKT1 MMP2 TP53
37 psammomatous meningioma 10.4 CTNNB1 MMP2 MMP9
38 nasal cavity squamous cell carcinoma 10.4 CDKN2A MMP2 MMP9
39 uterine carcinosarcoma 10.4 CDH1 CTNNB1 TP53
40 oropharynx cancer 10.4 CD6 CDH1 CDKN2A TP53
41 adenomyosis 10.3 CDH1 MMP2 MMP9
42 cervical squamous cell carcinoma 10.3 CDH1 CDKN2A CTNNB1 TP53
43 acute transverse myelitis 10.3 MMP2 MMP9
44 gliosarcoma 10.3 MMP2 MMP9 TP53
45 breast ductal carcinoma 10.3 CDH1 CTNNB1 TP53 VEGFC
46 ovarian cancer 1 10.3 AKT1 CDH1 MMP2 TP53
47 malignant ovarian surface epithelial-stromal neoplasm 10.3 AKT1 CDH1 MMP2 TP53
48 ovary epithelial cancer 10.3 AKT1 CDH1 MMP2 TP53
49 colonic disease 10.3 AKT1 CDH1 CTNNB1 TP53
50 meningioma, familial 10.3 AKT1 CDH1 CDKN2A TP53

Graphical network of the top 20 diseases related to Tongue Disease:



Diseases related to Tongue Disease

Symptoms & Phenotypes for Tongue Disease

UMLS symptoms related to Tongue Disease:


snoring, halitosis, oral manifestations, glossalgia, peeling tongue

MGI Mouse Phenotypes related to Tongue Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.9 AKT1 CD6 CDH1 CDKN2A CTNNB1 DNAJB7
2 digestive/alimentary MP:0005381 9.8 CDH1 CDKN2A CTNNB1 MMP9 SLC10A2 TBX22
3 neoplasm MP:0002006 9.5 AKT1 CDH1 CDKN2A CTNNB1 MMP2 MMP9
4 respiratory system MP:0005388 9.17 AKT1 CDKN2A CTNNB1 MMP2 MMP9 TBX22

Drugs & Therapeutics for Tongue Disease

Drugs for Tongue Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 138)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxycycline Approved, Investigational, Vet_approved Phase 4,Not Applicable 564-25-0 54671203
2
Cefuroxime Approved Phase 4,Not Applicable 55268-75-2 5479529 5361202
3
Amoxicillin Approved, Vet_approved Phase 4,Not Applicable 26787-78-0 33613
4
Penicillin V Approved, Vet_approved Phase 4 87-08-1 6869
5 Antiparasitic Agents Phase 4,Not Applicable
6 Anti-Bacterial Agents Phase 4,Phase 1,Phase 2,Not Applicable
7 Anti-Infective Agents Phase 4,Phase 2,Phase 1,Not Applicable
8 Antiprotozoal Agents Phase 4,Not Applicable
9 Antimalarials Phase 4,Not Applicable
10 Antibiotics, Antitubercular Phase 4,Phase 1,Phase 2,Not Applicable
11 cefuroxime axetil Phase 4,Not Applicable
12 penicillins Phase 4
13
Cisplatin Approved Phase 2, Phase 3,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
14
Cetuximab Approved Phase 2, Phase 3,Phase 1,Not Applicable 205923-56-4 56842117 2333
15
Docetaxel Approved, Investigational Phase 2, Phase 3,Phase 1 114977-28-5 148124
16 Immunoglobulins Phase 2, Phase 3,Phase 1,Not Applicable
17 Antimitotic Agents Phase 2, Phase 3,Phase 1
18 Antibodies, Monoclonal Phase 2, Phase 3,Phase 1,Not Applicable
19 Antibodies Phase 2, Phase 3,Phase 1,Not Applicable
20 Antineoplastic Agents, Immunological Phase 2, Phase 3,Phase 1,Not Applicable
21 Immunologic Factors Phase 2, Phase 3,Phase 1,Not Applicable
22
Fluorouracil Approved Phase 2,Phase 1 51-21-8 3385
23
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
24
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 38904 498142
25
Hydroxyurea Approved Phase 2,Phase 1 127-07-1 3657
26
leucovorin Approved Phase 2,Not Applicable 58-05-9 143 6006
27
Acetylcysteine Approved, Investigational Phase 2 616-91-1 12035
28 Raspberry Approved Phase 1, Phase 2,Not Applicable
29
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
30
Everolimus Approved Phase 1, Phase 2 159351-69-6 70789204 6442177
31
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 46835353 5284616 6436030
32
Sorafenib Approved, Investigational Phase 2,Phase 1 284461-73-0 216239 406563
33
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
34
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
35
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
36
Histamine Approved, Investigational Phase 2 51-45-6 774
37
Famotidine Approved Phase 2 76824-35-6 3325
38
nivolumab Approved Phase 2 946414-94-4
39
Promethazine Approved, Investigational Phase 2 60-87-7 4927
40
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
41
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
42
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
43
Gliclazide Approved Phase 2 21187-98-4 3475
44
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
45
Tegafur Approved, Investigational Phase 2 17902-23-7 5386
46
Inulin Approved, Investigational, Nutraceutical Phase 2 9005-80-5 24763
47
Saracatinib Investigational Phase 2 379231-04-6
48
Lapatinib Approved March 2007, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
49 Anesthetics Phase 2,Not Applicable
50 Antineoplastic Agents, Phytogenic Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 72)
# Name Status NCT ID Phase Drugs
1 Comparison of Doxycycline and Cefuroxime Axetil for Treatment of Erythema Migrans: Clinical and Microbiological Outcome Completed NCT01518192 Phase 4 doxycycline;cefuroxime axetil
2 Comparing 3 Antibiotic Regimes for Erythema Migrans in General Practice Completed NCT01368341 Phase 4 Doxycycline;Phenoxymethylpenicillin;Amoxicillin
3 Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Active, not recruiting NCT01810913 Phase 2, Phase 3 cisplatin;docetaxel
4 Role of Neo-adjuvant Chemotherapy in Tongue Preservation in Locally Advanced Squamous Cell Carcinoma of Oral Tongue Unknown status NCT02985255 Phase 2 Docetaxel;Cisplatin;5FU
5 PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Unknown status NCT01816984 Phase 1, Phase 2 PI3K inhibitor BKM120
6 Inulin and S. Salivarius Reduce Halitosis Completed NCT02794766 Phase 2 Inulin+SS;S salivarius;Placebo
7 Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy Completed NCT02123511 Phase 2 acetylcysteine
8 Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. Completed NCT01469429 Phase 1, Phase 2 chemoprevention;chemoprevention
9 Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer Completed NCT01316757 Phase 2 paclitaxel;carboplatin;erlotinib hydrochloride
10 Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma Completed NCT01195922 Phase 1, Phase 2 Sirolimus
11 Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab Completed NCT00939627 Phase 2 sorafenib tosylate
12 Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00513435 Phase 2 saracatinib
13 Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00507767 Phase 2 dasatinib
14 Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia Completed NCT00330382 Phase 2 Bowman-Birk inhibitor concentrate
15 Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00114283 Phase 2 lapatinib ditosylate
16 Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed NCT00103259 Phase 2 bortezomib;irinotecan hydrochloride
17 S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00096512 Phase 2 sorafenib tosylate
18 Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx Completed NCT00064103 Phase 1, Phase 2
19 Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00033618 Phase 2 ixabepilone
20 Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer Recruiting NCT03107182 Phase 2 nab-paclitaxel;Carboplatin;Nivolumab;Cisplatin;Hydroxyurea;5-FU;Dexamethasone;Famotidine;Diphenhydramine;Paclitaxel
21 Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene Recruiting NCT03602079 Phase 1, Phase 2 A166
22 S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis Recruiting NCT03499808 Phase 2
23 Correlation of FAZA PET Hypoxia Imaging To 3D Histology in Oral Tongue Cancer Recruiting NCT03181035 Phase 1, Phase 2 Pimonidazole
24 High-activity Natural Killer Immunotherapy for Small Metastases of Tongue Cancer Recruiting NCT03008330 Phase 1, Phase 2
25 Combination of Cryosurgey and NK Immunotherapy for Recurrent Tongue Cancer Recruiting NCT02849379 Phase 1, Phase 2
26 Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study Active, not recruiting NCT02748707 Phase 2 Arm1;Arm 2;Arm 3
27 18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Active, not recruiting NCT01806675 Phase 1, Phase 2 fludeoxyglucose F 18;2-fluoropropionyl-labeled pegylated dimeric RGD peptide
28 A Study of Tongue Conservation Surgery for Oral Tongue Cancer Terminated NCT03161548 Phase 2 Induction chemotherapy
29 Hypofractionated Radiation Therapy Followed by Surgery in Treating Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity Withdrawn NCT02295540 Phase 1, Phase 2
30 Radiation Therapy and Cisplatin With or Without Surgery in Treating Patients With Stage III-IV Oropharyngeal Cancer Withdrawn NCT01953952 Phase 2 cisplatin
31 Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy Withdrawn NCT01674374 Phase 2 Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia extract granules
32 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer Unknown status NCT01847326 Phase 1 carboplatin;paclitaxel albumin-stabilized nanoparticle formulation;fluorouracil;hydroxyurea
33 Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed NCT02035527 Phase 1 sorafenib tosylate;cisplatin;docetaxel
34 Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer Completed NCT01637194 Phase 1 everolimus
35 TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck Completed NCT01334177 Phase 1 TLR8 agonist VTX-2337
36 Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Completed NCT00397384 Phase 1 cetuximab;erlotinib hydrochloride
37 Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer Completed NCT00049283 Phase 1 erlotinib hydrochloride;docetaxel
38 Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer Terminated NCT01528137 Phase 1
39 Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck Terminated NCT00906360 Phase 1 sunitinib malate
40 Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy Withdrawn NCT01728480 Phase 1 entolimod;cisplatin
41 Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy Withdrawn NCT01332279 Phase 1 everolimus;erlotinib hydrochloride
42 HLA-DRB1 and HLA-DQB1 Genotyping for Autoantibody-positive and -Negative Patients With Atrophic Glossitis or Burning Mouth Syndrome Unknown status NCT01931293 Not Applicable
43 Effects of Different General Anesthesia Methods on Immune Responses in Patients Undergoing Surgery for Tongue Cancer Unknown status NCT01854021 Not Applicable
44 The Relationship Between Allergic Rhinitis and Geographic Tongue Unknown status NCT01454492
45 Antibiotic Treatment of Multiple Erythema Migrans Unknown status NCT01163994 Not Applicable ceftriaxone;doxycycline
46 Comparison of Doxycycline and Cefuroxime Axetil in Erythema Migrans Completed NCT03584919 Not Applicable doxycycline;Cefuroxime Axetil 500Mg Tab
47 Erythema Migrans in Elderly Completed NCT03371563 Antibiotics
48 Culture Media for Borrelia Burgdorferi Sensu Lato Completed NCT02145754 Not Applicable
49 Freeze-Dried Black Raspberries in Preventing Oral Cancer Recurrence in High-Risk Appalachian Patients Previously Treated With Surgery For Oral Cancer Completed NCT01504932 Not Applicable lyophilized black raspberry lozenge
50 Doxycycline in Therapy of Erythema Migrans Completed NCT01475708 Doxycycline

Search NIH Clinical Center for Tongue Disease

Cochrane evidence based reviews: tongue diseases

Genetic Tests for Tongue Disease

Genetic tests related to Tongue Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Tongue 30

Anatomical Context for Tongue Disease

MalaCards organs/tissues related to Tongue Disease:

42
Tongue, Colon, Skin, Ovary, Cervix, Pancreas, Thyroid

Publications for Tongue Disease

Articles related to Tongue Disease:

# Title Authors Year
1
Tongue disease in advanced AIDS. ( 15752079 )
2005

Variations for Tongue Disease

ClinVar genetic disease variations for Tongue Disease:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 SOX3 NM_005634.2(SOX3): c.735_737dupCGC (p.Ala248_Ser249insAla) duplication Uncertain significance rs398124211 GRCh37 Chromosome X, 139586489: 139586491
2 SOX3 NM_005634.2(SOX3): c.735_737dupCGC (p.Ala248_Ser249insAla) duplication Uncertain significance rs398124211 GRCh38 Chromosome X, 140504324: 140504326
3 46;XY;t(3;17)(p14.3;q24.3)dn Translocation Likely pathogenic
4 DNAJC21 NM_194283.3(DNAJC21): c.544C> T (p.Arg182Ter) single nucleotide variant Pathogenic GRCh37 Chromosome 5, 34937536: 34937536
5 DNAJC21 NM_194283.3(DNAJC21): c.544C> T (p.Arg182Ter) single nucleotide variant Pathogenic GRCh38 Chromosome 5, 34937431: 34937431
6 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
7 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539

Expression for Tongue Disease

Search GEO for disease gene expression data for Tongue Disease.

Pathways for Tongue Disease

Pathways related to Tongue Disease according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.77 AKT1 CDH1 CDKN2A CTNNB1 MMP9 TP53
2
Show member pathways
12.69 AKT1 CDH1 CDKN2A CTNNB1 TP53
3
Show member pathways
12.51 AKT1 CDH1 CDKN2A MMP2 MMP9 TP53
4 12.48 AKT1 CDH1 CDKN2A CTNNB1 MMP2 MMP9
5 12.36 AKT1 CDH1 CTNNB1 TP53
6 12.28 AKT1 CDKN2A CTNNB1 TP53
7
Show member pathways
12.28 AKT1 CDH1 CTNNB1 MMP2 MMP9 TP53
8 12.07 AKT1 CTNNB1 MMP2 MMP9 TP53
9 12.05 AKT1 CDH1 CTNNB1 TP53
10 11.98 CDKN2A CTNNB1 MMP2 TP53
11 11.91 CDH1 CTNNB1 MMP2 MMP9
12 11.87 AKT1 CDKN2A CTNNB1 TP53
13 11.85 AKT1 MMP2 MMP9 TP53
14 11.84 AKT1 MMP2 VEGFC
15 11.82 AKT1 CDKN2A CTNNB1 TP53
16 11.8 AKT1 CTNNB1 MMP2 MMP9 TP53
17
Show member pathways
11.79 AKT1 CTNNB1 VEGFC
18 11.77 MMP2 MMP9 VEGFC
19 11.68 AKT1 CDKN2A TP53
20
Show member pathways
11.67 AKT1 CDKN2A TP53
21 11.62 AKT1 MMP2 MMP9
22 11.62 CDKN2A CTNNB1 MMP2 TP53
23 11.61 AKT1 MMP2 MMP9
24 11.6 CDH1 CTNNB1 MMP2 MMP9
25 11.55 AKT1 CTNNB1 MMP9
26 11.51 CDKN2A TP53 VEGFC
27 11.48 CDKN2A MMP2 TP53
28 11.43 AKT1 MMP2 MMP9
29 11.42 AKT1 CDH1 MMP9
30 11.32 AKT1 CDH1 CTNNB1 MMP2 MMP9 TP53
31 11.23 AKT1 CDH1 CTNNB1
32 11.22 CDH1 CDKN2A MMP2 MMP9 TP53
33 11.05 AKT1 MMP2 MMP9
34 10.76 CDH1 CTNNB1

GO Terms for Tongue Disease

Cellular components related to Tongue Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 flotillin complex GO:0016600 8.62 CDH1 CTNNB1

Biological processes related to Tongue Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.67 AKT1 MMP2 MMP9 TP53
2 replicative senescence GO:0090399 9.32 CDKN2A TP53
3 morphogenesis of embryonic epithelium GO:0016331 9.26 CTNNB1 VEGFC
4 entry of bacterium into host cell GO:0035635 9.16 CDH1 CTNNB1
5 positive regulation of apoptotic process GO:0043065 9.02 AKT1 CDKN2A CTNNB1 MMP9 TP53
6 cellular response to indole-3-methanol GO:0071681 8.96 CDH1 CTNNB1

Molecular functions related to Tongue Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 GTPase activating protein binding GO:0032794 8.96 AKT1 CDH1
2 disordered domain specific binding GO:0097718 8.8 CDKN2A CTNNB1 TP53

Sources for Tongue Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....